Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence

Anson T. Ku, Uma Shankavaram, Shana Y. Trostel, Hong Zhang, Sumeyra Kartal, Houssein Abdul Sater, Stephanie A. Harmon, Nicole V. Carrabba, Yang Liu, Hyunnam Ryu, James A. Proudfoot, Boon Hao Hong, Bradford J. Wood, Peter A. Pinto, Peter L. Choyke, Mack Roach, Howard M. Sandler, Stephanie L. Pugh, Kenneth L. Zeitzer, Lucas C. Mendez, Nirav S. Kapadia, William A. Hall, Anand B. Desai, Radka Stoyanova, Alan Pollack, Elai Davicioni, Melvin L.k. Chua, Barış Türkbey, Adam G. Sowalsky, Deborah E. CitrinClinical 2025 · DOI

Abstract

TGF-β activity is a dominant feature of intermediate- to unfavorable-risk prostate tumors prone to biochemical failure after EBRT with ADT and may serve as an independent prognostic biomarker beyond existing clinical criteria.
BibTeX
@inproceedings{ku2025radiogenomic,
  author = {Anson T. Ku and Uma Shankavaram and Shana Y. Trostel and Hong Zhang and Sumeyra Kartal and Houssein Abdul Sater and Stephanie A. Harmon and Nicole V. Carrabba and Yang Liu and Hyunnam Ryu and James A. Proudfoot and Boon Hao Hong and Bradford J. Wood and Peter A. Pinto and Peter L. Choyke and Mack Roach and Howard M. Sandler and Stephanie L. Pugh and Kenneth L. Zeitzer and Lucas C. Mendez and Nirav S. Kapadia and William A. Hall and Anand B. Desai and Radka Stoyanova and Alan Pollack and Elai Davicioni and Melvin L.K. Chua and Barış Türkbey and Adam G. Sowalsky and Deborah E. Citrin},
  title = {{Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1078-0432.ccr-25-2186},
}

Loading related content...

Figure